Related Experiment Video
Updated: Jul 9, 2025
09:02
Optimizing Photoneuromodulation Techniques to Evaluate the Role of Green Light-Emitting Diodes in Pain Management
Published on: March 28, 2025
386
A Brief Review of Low-Level Light Therapy in Depression Disorder
Afshan Shirkavand1, Maryam Akhavan Tavakoli2, Zeinab Ebrahimpour3
1Department of Photodynamic Therapy, Medical Laser Research Center, YARA Institute, ACECR, Tehran, Iran.
Journal of Lasers in Medical Sciences
|November 29, 2023
Summary
Low-level laser therapy (LLLT), or photobiomodulation, shows promise for treating depression and neurodegenerative diseases. Further research into its mechanisms and clinical implementation is needed for enhanced patient quality of life.
Area of Science:
- Biomedical Engineering
- Neuroscience
- Photomedicine
Background:
- Low-level laser therapy (LLLT), also known as photobiomodulation (PBM), is increasingly recognized as a therapeutic modality.
- Visible and near-infrared (NIR) light have distinct biological effects and penetration depths.
Purpose of the Study:
- To review the application of LLLT for depression.
- To explore LLLT's mechanisms of action and pathways.
- To discuss limitations and challenges in clinical implementation.
Main Methods:
- Review of existing literature on LLLT applications in biological systems.
- Analysis of light wavelengths (400-700 nm visible, 800-1100 nm NIR) and their tissue penetration.
- Examination of preclinical studies on LLLT's effects on CNS diseases.
Main Results:
- LLLT enhances ATP production, improves blood flow, reduces inflammation, and promotes tissue repair and stem cell proliferation.
- Preclinical studies indicate neuroprotective effects of LLLT for Alzheimer's and Parkinson's disease models.
- LLLT shows potential for ameliorating mental disorders, including depression.
Conclusions:
- LLLT offers a promising therapeutic avenue for various conditions, including CNS diseases and depression.
- A deeper understanding of LLLT's protective effects and mechanisms is crucial for its future clinical use.
- LLLT has the potential to significantly improve patients' quality of life.
Related Concept Videos
01:18Depression: Overview
252
Depression is a prevalent mental illness marked by persistent sadness and lack of interest in previously enjoyable activities. It can take several forms, including major depression, persistent depressive disorder, and bipolar I and II disorders. Symptoms range from emotional changes like chronic worry to physical changes like sleep disturbances and suicidal thoughts. From a neurobiological perspective, depression is believed to be triggered by abnormalities in the brain's prefrontal cortex,...
252
01:30Electroconvulsive Therapy
44
Electroconvulsive therapy (ECT), or shock therapy, remains a critical biomedical intervention for severe, treatment-resistant depression. While its origins can be traced back to Hippocrates' observations that malaria-induced convulsions alleviated mental illness, modern ECT has evolved significantly from its earlier, more primitive applications. First introduced in 1938 by Ugo Cerletti and his colleagues, ECT involves inducing controlled seizures using electrical currents. In its early...
44
01:27Depressive Disorders: MDD and Dysthymia
136
Depressive disorders are a group of mental health conditions characterized by pervasive feelings of sadness, diminished pleasure in life, and a significant impact on daily functioning. These conditions are most prevalent in individuals during their 30s and affect women at twice the rate of men. Contrary to popular belief, younger individuals are generally more susceptible to these disorders than older adults. Two key types of depressive disorders include Major Depressive Disorder (MDD) and...
136
01:23Antidepressant Drugs: MAOIs and Other Agents
248
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
248
01:03Long-term Depression
2.5K
Long-term depression, or LTD, is one of the ways by which synaptic plasticity—changes in the strength of chemical synapses—can occur in the brain. LTD is the process of synaptic weakening that occurs over time between pre and postsynaptic neuronal connections. The synaptic weakening of LTD works in opposition to synaptic strengthening by long-term potentiation (LTP) and together are the main mechanisms that underlie learning and memory.
Calcium Ion Concentration Mechanism
If over...
Calcium Ion Concentration Mechanism
If over...
2.5K
01:27Depressive Disorders: Etiology
103
Depressive disorders result from a complex interplay of biological, psychological, and sociocultural factors, each contributing uniquely to the development and persistence of the condition. Understanding these factors provides critical insight into the multifaceted nature of depression.
Biological Factors in Depression
Biological predispositions significantly influence the risk of developing depressive disorders. Genetic studies highlight the role of variations in the serotonin transporter...
Biological Factors in Depression
Biological predispositions significantly influence the risk of developing depressive disorders. Genetic studies highlight the role of variations in the serotonin transporter...
103